Fourth Volume of Popular eMultipleScleroris Review Series Launches for Clinicians

Fourth Volume of Popular eMultipleScleroris Review Series Launches for Clinicians
Contact: Matt Miller
Phone: 646-336-6495
Fax: 646-336-6497
Email: [email protected]

NEW YORK (1/17/2022) – DKBmed, LLC, in collaboration with the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing, is launching a fourth volume of its eMultipleSclerosis Review. This online literature review series curates the latest medical literature and explains how clinicians can apply the information presented in clinical practice. Volume 3 of eMultipleSclerosis Review was a resounding success, with over 6,000 participants, 4,500 app downloads, and over 7,000 page views - 96% of participants reported knowledge gains, with 69% noting that they intended to change their practice based on the information they learned.

The program can be found at emultiplesclerosisreview.org

Multiple sclerosis is estimated to affect approximately 2.1 million people worldwide. With no known cure, MS is a lifelong condition that ranks second behind congestive heart failure in direct, all-cause medical costs. While the search for curative treatments continues, multiple disease-modifying treatments (DMTs) have emerged in recent years to treat patients with relapsing-remitting MS (RRMS). People with progressive forms of MS have fewer DMT options.

“The treatment of multiple sclerosis is continually evolving, and the growing amount of literature on the disease is overwhelming, even for the most diligent of clinicians” notes Joseph Sabatino, Jr., MD, PhD, Assistant Adjunct Professor, Department of Neurology at University of California San Francisco and guest author of eMultipleSclerosis Review. “A resource like eMultipleSclerosis Review is very helpful for clinicians, and I’m pleased that there will be future activities to help stay up to date on the latest developments in MS.”

Volume 4 of the eMultipleSclerosis Review will cover pertinent topics in the care of patients with MS, including:

  • The effects of different DMTs on COVID-19 vaccine response
  • Nonpharmacologic approaches to symptom management
  • Newly approved and emerging therapies demonstrating promise in clinical trials
  • Optimizing management of MS in older populations
  • Recent advances in minimizing and preventing misdiagnoses of MS
  • Caring for patients from different racial and ethnic backgrounds

eMultipleSclerosis Review is one component of the highly successful and popular eLiterature Review series published through DKBmed’s collaboration with the Johns Hopkins School of Medicine and the Institute for Johns Hopkins Nursing. Each installment consists of a newsletter and podcast. To view this and similar learning programs centered on other conditions, including cystic fibrosis, HIV, and COPD, visit elit.dkbmed.com.

Credit Designation Statements

Physicians
eNewsletter: The Johns Hopkins University School of Medicine designates this enduring material – Internet activity for a maximum 6.0 AMA PRA Category 1 CreditsTM (1 AMA PRA Category 1 CreditTM per monthly review). Physicians should only claim credit commensurate to the extent of their participation in the activity.
Podcast: The Johns Hopkins University School of Medicine designates this enduring material – Internet activity for a maximum of 3.0 AMA PRA Category 1 CreditsTM.

Nurses
eNewsletter: This 1 contact hour Educational Activity is provided by the Institute for Johns Hopkins Nursing. Each Newsletter carries a maximum of 1 contact hour, or a total of 6.0 contact hours for the 6 newsletters in this program. ​ Podcast: These paired, 0.5 contact hour Educational Activities are provided by the Institute for Johns Hopkins Nursing. Each podcast carries a maximum of 0.5 contact hour, or a total of 3.0 contact hours for the 6 podcasts in the program.

Disclosure of Support

​ Volume 4 of the eMultipleSclerosis Review is supported by educational grants provided by Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, and Sanofi Genzyme.

About DKBmed

​ DKBmed is an integrated continuing medical education company operated by an experienced team of medical education experts. DKBmed provides health care professionals with effective medical education that closes identified knowledge and practice gaps to improve patient health.

Working with accredited providers and other partners, DKBmed develops innovative educational programs and quality improvement (QI) initiatives, bringing new learning methodologies to the CME landscape. DKBmed has become a leader in QI in the independent medical education space with QI projects in Pain Management, HIV, Depression, Influenza, and Diabetic Eye Disease. DKBmed was also an early adopter of case scenarios with real patients and live actors, TED/DKBmed Talks, 3D animation, webcasts, podcasts, and smart phone applications for clinicians and patients. These forward-thinking approaches enable health care professionals to learn and access educational programs in a manner that is most convenient and appropriate for them.

DKBmed’s programs are accessible through the company’s website (www.dkbmed.com). They reach more than 150,000 health care professionals in primary care and in a variety of specialties and disease states including: HIV, COVID-19, cystic fibrosis, diabetes, influenza, dermatology, retinal disease, rheumatoid arthritis, COPD, asthma, multiple sclerosis, pain management, depression and viral hepatitis (HBV, HCV) and oncology.